KRAS and non-small cell lung carcinoma: Moreover, the TP53 co-mutation with EGFR/STK11/KRAS/ATM has been proved to have the predictive value for the outcome of ICIs in NSCLC (Chen et al. 2019; Dong et al. 2017; Biton et al. 2018; Skoulidis et al. 2015).